Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06219915 · ClinicalTrials.gov registry record · Phase 1
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT06219915: Completed Phase 1 study, sponsored by University of Michigan.
NCT06219915 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06219915, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that \~20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this double-blinded, placebo-controlled study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.
Primary Outcome
Average gait speed as measured using wearable sensors and while walking on a sensor mat. Measured in meters per second.
Interventions
- DRUG Placebo 1
- DRUG Placebo 2
- DRUG Carbidopa 25 mg
- DRUG Carbidopa-Levodopa 25/100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 1 |
What the finished NCT06219915 record still lists
NCT06219915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo 1 is the first listed.
NCT06219915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06219915 about?
NCT06219915 is a clinical study titled "Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm". Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking imp...
What is the current status of trial NCT06219915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2024-03-15. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT06219915?
The interventions under investigation include: Placebo 1 (DRUG), Placebo 2 (DRUG), Carbidopa 25 mg (DRUG), Carbidopa-Levodopa 25/100 mg (DRUG).
Who is sponsoring clinical trial NCT06219915?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06219915's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI